The Food and Drug Administration has approved of the use of a drug called Gleevec for children who have acute lymphoblastic leukemia. It has previously been approved to treat adult patients with several conditions. Gleevec is marketed by Novartis. On January 25, 2013, the Food and Drug Administration (FDA) approved of the use of a drug called Gleevec for children who have acute lymphoblastic leukemia. Gleevec is also called imatinib. It has been specifically approved to treat kids who have been newly diagnosed with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia. (ALL). ALL is a fast-growing cancer of the white … Continue reading →